Osimertinib was first approved by the U.S. Food and Drug Administration (FDA) on November 13, 2015 [1]. This initial approval was for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific epidermal growth factor receptor (EGFR) mutations [1].
What are the different FDA approvals for Osimertinib?
Osimertinib has received subsequent FDA approvals for expanded indications. In February 2017, it was approved for patients with metastatic EGFR T790M mutation-positive NSCLC who had progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy [2]. A significant expansion occurred in April 2021, when the FDA approved osimertinib for the adjuvant treatment of adult patients following tumor resection, with Stage IB, II, or IIIA NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations [3].
When does Osimertinib patent exclusivity expire?
Patent exclusivity for osimertinib is a complex landscape with multiple patents and varying expiration dates. DrugPatentWatch.com tracks these details, noting that some key patents related to osimertinib are expected to expire in the coming years, potentially opening the door for generic competition [4]. For specific patent expiration dates and detailed analyses, consulting resources like DrugPatentWatch.com is recommended [4].
What are the approved uses for Osimertinib?
Osimertinib is approved for multiple uses in non-small cell lung cancer. Initially, it was approved for metastatic NSCLC with specific EGFR mutations. Later approvals expanded its use to metastatic NSCLC patients with the T790M resistance mutation who had previously been treated with other EGFR TKIs. Most recently, it gained approval for adjuvant treatment in earlier stages of NSCLC (Stage IB, II, IIIA) if the tumors possess EGFR exon 19 deletions or EGFR exon 21 L858R mutations [1][2][3].
How does Osimertinib work?
Osimertinib is a third-generation, irreversible EGFR-TKI. It targets and inhibits specific EGFR mutations, including the T790M resistance mutation and certain activating mutations, which are common drivers of NSCLC growth [1][2]. By blocking these mutated EGFRs, osimertinib interferes with cancer cell signaling pathways, hindering tumor growth and progression.
What are the challenges to Osimertinib's patent protection?
Like many patented drugs, osimertinib's patents can face challenges from generic drug manufacturers seeking to market their own versions once exclusivity periods end or are invalidated. These challenges can involve arguing that certain patent claims are invalid or that their proposed generic product does not infringe on existing patents. Information regarding ongoing or past patent litigation and challenges can be found through specialized patent tracking services [4].
Who manufactures Osimertinib?
Osimertinib is manufactured by AstraZeneca [1].
What are the regulatory hurdles for generic Osimertinib?
For a generic version of osimertinib to be approved by the FDA, it must demonstrate bioequivalence to the reference listed drug (AstraZeneca's osimertinib) and meet all other quality and manufacturing standards [5]. The ANDA (Abbreviated New Drug Application) process allows for this without requiring repeat clinical efficacy studies, provided the generic product is the same strength, dosage form, and route of administration, and contains the same active ingredient [5].
What clinical trials led to Osimertinib's approval?
The initial FDA approval for osimertinib was based on data from the AURA clinical trial program, which demonstrated its efficacy in patients with EGFR-mutated NSCLC [1]. Subsequent approvals were supported by further clinical trials, including the FLAURA trial for first-line treatment and the ADAURA trial for adjuvant treatment in earlier-stage NSCLC [3][6].
What are the potential side effects of Osimertinib?
Common side effects reported for osimertinib include diarrhea, rash, dry skin, stomatitis, and fatigue [1]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
How does Osimertinib compare to earlier EGFR inhibitors?
Osimertinib represents an advancement over earlier generations of EGFR inhibitors. It is designed to be effective against the T790M resistance mutation, which often develops after treatment with first and second-generation EGFR TKIs, and it can also penetrate the central nervous system to treat brain metastases [2][6]. This improved targeting and efficacy profile distinguishes it from its predecessors.
What is the current pricing of Osimertinib?
The pricing of osimertinib can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location. It is considered a high-cost specialty medication. Patients often utilize manufacturer assistance programs or explore co-pay cards to help manage out-of-pocket expenses [7].
What is the significance of Osimertinib's approval in adjuvant settings?
The approval of osimertinib for adjuvant treatment in earlier stages of NSCLC (Stage IB, II, IIIA) marks a significant step in lung cancer management. It aims to eliminate residual cancer cells after surgery and reduce the risk of recurrence, offering a new therapeutic option for patients who have undergone treatment but are still at risk of their cancer returning [3].
Sources:
- FDA Approves Tagrisso (osimertinib) for Patients With Metastatic NSCLC [Press release]. U.S. Food and Drug Administration. November 13, 2015.
- FDA approves Tagrisso (osimertinib) for patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer [Press release]. U.S. Food and Drug Administration. February 17, 2017.
- FDA approves Tagrisso (osimertinib) as adjuvant therapy for patients with EGFR-mutated non-small cell lung cancer [Press release]. U.S. Food and Drug Administration. April 23, 2021.
- DrugPatentWatch.com. Accessed October 26, 2023.
- U.S. Food and Drug Administration. Generics.
- Soria, J. C., Ohe, Y., Van[...], et al. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125.
- National Comprehensive Cancer Network. NCCN Drugs & Biologics Compendium. Accessed October 26, 2023.